Alzinova AB’s Post

📣 Dive Deeper into STING & TLR Innovations! 🚀 Missed our recent webinar, "Harnessing STING & TLR: Current Developments, Clinical Trials, and Key Players in the Landscape"? Don't worry, you can still catch up! Watch the session on demand to explore the latest advancements in the STING & TLR pipeline, discover new combination therapies, and dive into innovative strategies shaping the future of treatment. 🔗 Watch Now: https://ter.li/z3x8at Stay informed and ahead in the dynamic field of STING & TLR-targeted therapies! #ImmunoOncology #STING #TLR #Checkpoint

It's time for our Citeline Monthly Highlights! Here are some of September's latest news and updates from our Citeline brands. Check out the links below. 👇 We are proud to join forces with Greenphire, this partnership is a huge step in how we will create next generation products at Citeline. Read how our complementary datasets will support sponsors and CROs in clinical trial planning! https://ow.ly/nUg050TEfzo. Citeline Connect seamlessly blends technology and services to expand recruitment channels and accelerate study enrollment. This integrated, modular solution can be tailored to specific needs so you can effortlessly meet your enrollment targets: https://ow.ly/JAOm50TEfzm. Ensuring reliable disclosure practices has evolved beyond a mere regulatory requirement for clinical trial professionals. Is your organization keeping up? Find out in the first of our clinical trial disclosure maturity model series: https://ow.ly/p2eH50TEfzk. Founder of autism therapy digital therapeutic firm Floreo, spoke to Medtech Insight about working with the FDA and why the TAP pilot made sense for them: https://ow.ly/xC7U50TEfzn. Don't miss our upcoming webinar: Unlock Global Access to Advanced Therapies! Join us on October 9 to discover how data insights can break down barriers in middle and low-income countries, expanding access to critical CGTs: https://ow.ly/MLGk50TEfzl.

Our team have had a busy few days at BIO-Europe Spring this week, connecting with both new and existing customers. Marianna Sciortino shares some key highlights from the conference. Missed us at BIO-Europe? Book an exploratory meeting with one of our solution experts using the link below to: ·  Learn more about how our Physician Engage services enables you to identify and engage physicians at the optimum time in the treatment decision window to increase patient identification and support therapy adoption. ·  Discover how Diaceutics Market Landscape can optimize your commercial strategy by providing insights into the testing landscape, driving test adoption for your precision medicine diagnostic. ·  Find out more about our Lab Engage services that enable you to communicate directly with labs, utilizing our global lab network to influence biomarker testing behaviors and drive testing rates. https://lnkd.in/duuUdunz #BIOEuropeSpring

Exciting to hear about the advances in lung cancer research and treatment modalities in development for ALK positive lung cancer. #alkpositive #research #lungcancerresearch

Excited about the #EONS_SubcutaneousImmunotherapysymposium? We are! Don’t miss insightful sessions on SC immunotherapy, safe administration, & managing side effects. See you on Sep 15, 12:00 – 13:30 hrs CEST at Fira Barcelona Gran Via! Join the conversation with Lena Sharp, Guillermo De Velasco Oria de Rueda, Zoe O’Neil and Eva Muñoz Couselo, MD, PhD using hashtags #EONS17, #ESMO24 and #EONS_SubcutaneousImmunotherapy Event supported by Bristol Myers Squibb

I can’t wait to connect and collaborate at BIO 2024. Especially eager to discuss pain points in clinical development pipelines. You can contact me by email. Or request a meeting via the BIO partnering system: https://lnkd.in/gzSnamDw Want to hear how autoantibodies can enable precision medicine? Oncimmune’s CEO Martin Gouldstone and other panel members will be discussing just that: https://lnkd.in/gtN_cV_7 #BIO2024 #Oncimmune #autoantibodies #precisionmedicine

The therapeutic window for anti-CTLA-4 therapy has been an outstanding challenge for so many years including most first and second generation anti-ctla-4 therapies! The therapeutic window is well reflected by the RP2D used in combination with anti-PD-1; for example, if NO premedication such as steroid or anti-IL6 or anti-TNFa etc is used, few second generation anti-CTLA-4 therapies in combination with anti-PD1/PD-L1 has go beyond RP2D used by ipilimumab or tremelimumab, the first generation anti-CTLA-4 therapies receiving FDA approval. For reference, ipi is dosed at 1 mpk (~75 mg in flat dose) q6w continuously or 3 mpk (~225 mg in flat dose) for up to 4 cycles in combination with nivolumab. An unprecedented improvement in therapeutic window for ADG126, anti-CTLA-4 SAFEbody, enables us to dose it at 10 mpk Q3/6W continuously (>4 cycles) in combination with Pembro to unleash therapeutic efficacy in advanced MSS CRC pts where Pembro monotherapy has minimal efficacy...

On #LimbGirdleAwarenessDay, we’re proud to announce the launch of C-Path’s new task force dedicated to advancing drug development for limb-girdle muscular dystrophies. Under the Rare Disease Cures Accelerator-Data and Analytics Platform, this collaborative effort unites experts from leading organizations to tackle the unmet medical needs in the LGMD community. This task force includes pivotal members: ML Bio Solutions (BridgeBio), Coalition to Cure Calpain 3, CURE LGMD2I FOUNDATION, Jain Foundation Inc, LGMD2D Foundation, LGMD2i Research Fund and The Speak Foundation. Together, we’re leveraging patient-level data, shared knowledge, and a neutral platform to expedite therapeutic advancements for those affected by LGMDs. As we work toward accelerating meaningful progress, our commitment remains to ensure patient voices and data drive innovation. Read the full details, here: https://lnkd.in/gFiffMB3 Alexandre Bétourné, PhD, PharmD, PMP Heidi Grabenstatter Douglas Sproule Kat Bryant Knudson Ramona Belfiore-Oshan Rachel DeConti Adora Ndu, PharmD, JD Anna Wade Cybele Gouverneur Jean-Pierre Laurent Jennifer Levy Jessica Evans Kelly Brazzo Laura Rufibach Patrick Moeschen #CPath #LimbGirdleMuscularDystrophy #RareDiseaseResearch #DataCollaboration #DrugDevelopment #DataSharing #RDCADAP #PatientVoice #Collaboration

It started with a seemingly simple ambition: enabling medical professionals to share their reports with a single click. // In reality, this was not simple at all: Lifen invested huge technical and operational efforts. The result? An average time-saving of ⏳ 3 hours per day per medical secretary, and stronger collaboration between city practices and hospitals 🏥. 💪💪💪 🤩 Today, Lifen offers much more! After a pilot project with Gustave Roussy to build the LUCC multicenter cohort, aimed at characterizing lung cancer patients 🫁 (over 3,000 patients from 17 centers in under 9 months), Lifen is accelerating the development of Lifen DataLab: a solution to collect and structure real-world patient data for clinical research—a time-consuming and costly process today. Lifen and #France2030 (operated by Bpifrance) have just announced a €15M investment 💶 to boost the development of DataLab. The hospital environment and care pathways between city and hospital are notoriously complex, and large-scale adoption only happens when tools prove their worth in real-world settings. For healthcare entrepreneurs, focusing on solving one 'simple' problem on the ground, before moving to fancier ambitions seems to be the right approach 💡. Congratulations to Lifen co-founders Franck Le Ouay, Etienne Depaulis, and Alexandre Huckert for driving forward projects that are advancing medicine! Grateful to have you on board with 50 Partners Health! 🙌 Bravo to Lifen's clinical partners, institutional partners, and investors, who are making this happen! 👏 Benjamin Besse Pierre Moustial Jean-Marc Patouillaud Clara Chappaz Thibault Naline and many more 👏

Key Tech’s Andy Rogers and Lauren Eskew discuss this exciting development with Astek Diagnostics co-founder and CEO Mustafa Al-Adhami, Ph.D. In the clip below learn how Astek is working to transition beyond UTI diagnosis and planning to utilize its core science to address other major clinical needs.